PROJECT BRIEF. Overview
PROJECT BRIEF. 3.1 The Additional Client shall then issue to the proposed Appointed Company an invitation to submit an offer in writing setting out details of the Project, the Project Contract Conditions to be used, the relevant pricing model or price framework, and the timetable for the return of the invitation to the Additional Client and other matters relating to the Project, using Schedule 5 Part 3 as a reference.
PROJECT BRIEF. Part 1 The Services
PROJECT BRIEF. Services Introduction
PROJECT BRIEF. 3.1 The LHC Client shall then issue to the proposed Appointed Company an invitation to submit an offer in writing setting out details of the Project, the Project Contract Conditions to be used, the relevant pricing model or price framework, and the timetable for the return of the invitation to the LHC Client and other matters relating to the Project, using Schedule 5 Part 3 as a reference.
PROJECT BRIEF. Project Name Dualization of Lokoja- Benin Road, Section II, Okene-Auchi, In Kogi/Edo States
PROJECT BRIEF. 1.1 The Parties shall agree upon the project brief, product backlog, specification and/or requirements either before or after the Commencement Date, as set out in the Agreement. If the Project Brief is agreed prior to the date of the Agreement, it shall be attached thereto.
1.2 The project brief, product backlog, specification and/or requirements shall set out, in full, the Services required by the Client.
1.3 Either Party may request or propose amendments to the project brief, product backlog, specification and/or requirements. Any proposed amendments must be made in writing. If either Party wishes to discuss such issues, at a meeting that Party shall provide at least 2 days’ notice of the meeting to the other Party.
PROJECT BRIEF. 2.1 Scope of Work
2.2 Project Requirements Description of Requirement Priority
1.3 Deliverables [remove if not applicable]
PROJECT BRIEF. Defibrotide is a single-stranded polydeoxyribonucleotide extracted from porcine intestinal mucosa. It has been shown that Defibrotide has protective effects on vascular endothelial cells, particularly those of small vessels. Defibrotide has antithrombotic, anti inflammatory and antiischaemic properties. After binding to endothelial cells Defibrotide enhances fibrinolysis. These effects of Defibrotide appear to be predominantly localized within the vascular bed, and there appear to be no significant effects on systemic coagulation. Favorable responses have been seen in previous clinical studies in about 45% of patients treated with Defibrotide for the treatment of Severe Hepatic Xxxx-Occlusive Disease (VOD). There have also been no significant toxicities related to the study drug in the majority of patients treated in previous clinical studies. Recent preclinical studies have demonstrated that Defibrotide used in conjunction with Granulocyte Colony-Stimulating Factor (rhG-CSF) significantly increases the number of Peripheral Blood Progenitor Cells (Stem cells). The benefit of this increase in stem cells may be crucial for a variety of clinical indications, including graft engineering procedures and gene therapy programs. Manufacturing process steps: Solution Preparation, Filling, Inspection, Secondary Packaging. Terminal sterilization is not required.
PROJECT BRIEF. Integrated Tamarind Processing Unit
